UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check one): [X] Form 10-K [  ] Form 20-F [  ] Form 11-K [  ] Form 10-Q [  ] Form 10-D [  ] Form N-SAR

[  ] Form N-CSR

For Period Ended: December 31, 2017

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I — REGISTRANT INFORMATION

Marathon Patent Group, Inc.

Full Name of Registrant

Former Name if Applicable

11601 Wilshire Blvd., Ste. 500

Address of Principal Executive Office (Street and Number)

Los Angeles, CA 90025

City, State and Zip Code

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The Company has encountered a delay in assembling the information, in particular its financial statements for the year ended December 31, 2017, required to be included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2017 (the “Annual Report”). The Company expects to file its Annual Report with the U.S. Securities and Exchange Commission within 15 calendar days of the prescribed due date.

PART IV — OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed ? If answer is no, identify report(s). Yes [X] No[  ]

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof ?

Yes [X] No [  ]

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

The Company’s revenue for the year ended December 31, 2017 was $519,622, compared to $36,629,276 for the year ended December 31, 2016. This represents a year-over-year decrease in revenue of $36,109,654, which represents a 99% decrease in 2017 compared to 2016. The decrease in revenue in 2017 resulted primarily from an overall decline in patent licensing revenue during which the Company, as well as its competitors, faced considerable headwinds in our industry, as compared to 2016 during which we entered into a number of sizable licenses through our subsidiaries, Dynamic Advances, LLC, and Orthophoenix, LLC.

Has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.